Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896371 | 0.79 | MTNR1A (0.77) | CA12CA14CA1CA2CA9 | |
| SCHEMBL5724835 | 0.79 | CA12 (0.74) | CA12CA14CA1CA2CA9 | |
| SCHEMBL4600464 | 0.77 | CA12 (0.66) | CA12CA14CA1CA2CA9 | |
| SCHEMBL3209241 | 0.76 | CA12 (0.60) | CA12CA14CA9TAAR1KDM4E | |
| SCHEMBL3535994 | 0.75 | CA12 (0.63) | CA12CA14CA1CA2CA9 | |
| SCHEMBL30822632 | 0.75 | CA12 (0.63) | CA12CA14CA1CA2CA9 | |
| SCHEMBL15637306 | 0.74 | MTNR1A (0.63) | CA12CA14CA1CA2CA9 | |
| SCHEMBL14241869 | 0.74 | MTNR1A (0.72) | CA12CA14CA1CA2CA9 | |
| SCHEMBL27593132 | 0.74 | MTNR1A (0.63) | MTNR1AMTNR1BHPGDTAAR1MPO | |
| SCHEMBL1010724 | 0.73 | MTNR1A (1.00) | MTNR1AMTNR1BHPGDTAAR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA14 2880/4885CA1 3460/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3135/4885CA14 3444/4885CA1 3746/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA14 2880/4885CA1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.